psoriasis vulgaris
Conditions
Interventions
Control group:Use Calcipotriol
Experimental group:Use Calcipotriol + Ceramide Repair Moisturizer
Sponsors
Shanghai Dermatology Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Volunteers who meet the diagnosis and treatment criteria for mild to moderate psoriasis vulgaris, that is, body surface involvement (BSA) <= 10% and PASI score <= 10; 2. Adults over the age of 18 years, regardless of gender; 3. The trial has not received systemic biologic therapy known to affect psoriasis before the trial; 4. Those who have not received ultraviolet phototherapy, photochemotherapy or systemic psoriasis drug treatment (such as glucocorticoids, retinoic acid or immunosuppressive agents) within 4 weeks before the trial; 5. Have not received local anti-psoriasis treatment (including local glucocorticoids and vitamin D derivatives) within 2 weeks before the trial; 6. Fully understand the content of the trial, voluntarily participate in the trial, be able to follow the doctor's advice, follow up, and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women; 2. Known history of hypersensitivity to study product ingredients or similar products; 3. Have a history of serious heart, liver, kidney and blood diseases, and other skin diseases such as lupus erythematosus and pemphigus; 4. Suffering from other skin diseases that may interfere with the clinical evaluation of psoriasis and or bring danger to the patient; 5. Participated in clinical research of any other drug within 3 months before the start of the trial; 6. Poor compliance, unable to adhere to follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Psoriasis Lesion Area and Severity Index Score;Transepidermal water loss;Erythema index; | — |
Secondary
| Measure | Time frame |
|---|---|
| stratum corneum water content;pH;Skin lipid structure detection;skin blood flow test;Dermatology Life Quality Index (DLQI);Product use evaluation;Product tolerability and safety evaluation; | — |
Countries
China
Contacts
Public ContactShi Yuling
Shanghai Dermatology Hospital
Outcome results
None listed